<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35366559</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-8421</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>367</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neuroimmunology</Title>
          <ISOAbbreviation>J Neuroimmunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The clinical need for clustered AChR cell-based assay testing of seronegative MG.</ArticleTitle>
        <Pagination>
          <StartPage>577850</StartPage>
          <MedlinePgn>577850</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jneuroim.2022.577850</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0165-5728(22)00045-5</ELocationID>
        <Abstract>
          <AbstractText>Trial eligibility in myasthenia gravis (MG) remains largely dependent on a positive autoantibody serostatus. This significantly hinders seronegative MG (SNMG) patients from receiving potentially beneficial new treatments. In a subset of SNMG patients, acetylcholine receptor (AChR) autoantibodies are detectable by a clustered AChR cell-based assay (CBA). Of 99 SNMG patients from two academic U.S. centers, 18 (18.2%) tested positive by this assay. Autoantibody positivity was further validated in 17/18 patients. In a complementary experiment, circulating AChR-specific B cells were identified in a CBA-positive SNMG patient. These findings corroborate the clinical need for clustered AChR CBA testing when evaluating SNMG patients.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Masi</LastName>
            <ForeName>Gianvito</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT 06511, USA; Department of Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yingkai</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Neuromuscular Division, Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Karatz</LastName>
            <ForeName>Tabitha</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Neuromuscular Division, Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pham</LastName>
            <ForeName>Minh C</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oxendine</LastName>
            <ForeName>Seneca R</ForeName>
            <Initials>SR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT 06511, USA; Department of Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nowak</LastName>
            <ForeName>Richard J</ForeName>
            <Initials>RJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT 06511, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guptill</LastName>
            <ForeName>Jeffrey T</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>Neuromuscular Division, Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA; Duke Clinical Research Institute, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Connor</LastName>
            <ForeName>Kevin C</ForeName>
            <Initials>KC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Yale School of Medicine, New Haven, CT 06511, USA; Department of Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA. Electronic address: kevin.oconnor@yale.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AI114780</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 AI164590</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Neuroimmunol</MedlineTA>
        <NlmUniqueID>8109498</NlmUniqueID>
        <ISSNLinking>0165-5728</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011950">Receptors, Cholinergic</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001681" MajorTopicYN="N">Biological Assay</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009157" MajorTopicYN="Y">Myasthenia Gravis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011950" MajorTopicYN="Y">Receptors, Cholinergic</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Autoantibodies</Keyword>
        <Keyword MajorTopicYN="Y">Cell-based assay</Keyword>
        <Keyword MajorTopicYN="Y">Myasthenia gravis</Keyword>
        <Keyword MajorTopicYN="Y">Seronegative</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>6</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>20</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35366559</ArticleId>
        <ArticleId IdType="mid">NIHMS1794257</ArticleId>
        <ArticleId IdType="pmc">PMC9106915</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jneuroim.2022.577850</ArticleId>
        <ArticleId IdType="pii">S0165-5728(22)00045-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Budhram A, Dubey D, Sechi E, Flanagan EP, Yang L, Bhayana V, McKeon A, Pittock SJ, Mills JR, 2020. Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis. Clin. Chem
66, 1496–1509. 10.1093/clinchem/hvaa254</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/clinchem/hvaa254</ArticleId>
            <ArticleId IdType="pubmed">33221892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Devic P, Petiot P, Simonet T, Stojkovic T, Delmont E, Franques J, Magot A, Vial C, Lagrange E, Nicot AS, Risson V, Eymard B, Schaeffer L, 2014. Antibodies to clustered acetylcholine receptor: expanding the phenotype. Eur. J. Neurol
21, 130–134. 10.1111/ene.12270</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.12270</ArticleId>
            <ArticleId IdType="pubmed">24112557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engel AG, Shen X-M, Selcen D, Sine SM, 2015. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol. 14, 420–434. 10.1016/S1474-4422(14)70201-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(14)70201-7</ArticleId>
            <ArticleId IdType="pmc">PMC4520251</ArticleId>
            <ArticleId IdType="pubmed">25792100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gasperi C, Melms A, Schoser B, Zhang Y, Meltoranta J, Risson V, Schaeffer L, Schalke B, Kroger S, 2014. Anti-agrin autoantibodies in myasthenia gravis. Neurology
82, 1976–1983. 10.1212/WNL.0000000000000478</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000478</ArticleId>
            <ArticleId IdType="pubmed">24793185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gastaldi M, Scaranzin S, Jarius S, Wildeman B, Zardini E, Mallucci G, Rigoni E, Vegezzi E, Foiadelli T, Savasta S, Banfi P, Versino M, Benedetti L, Novi G, Mancardi MM, Giacomini T, Annovazzi P, Baroncini D, Ferraro D, Lampasona V, Reindl M, Waters P, Franciotta D, 2020. Cell-based assays for the detection of MOG antibodies: a comparative study. J. Neurol
267, 3555–3564. 10.1007/s00415-020-10024-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-020-10024-0</ArticleId>
            <ArticleId IdType="pubmed">32623596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM, 2019. Myasthenia gravis. Nat. Rev. Dis. Primer
5, 30. 10.1038/s41572-019-0079-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41572-019-0079-y</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus YF, de Baets MH, van Breda Vriesman PJ, Burton DR, 1997. Anti-acetylcholine receptor Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. Immunol. Lett
57, 59–62. 10.1016/S0165-2478(97)00046-l</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-2478(97)00046-l</ArticleId>
            <ArticleId IdType="pubmed">9232426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higuchi O, Hamuro J, Motomura M, Yamanashi Y, 2011. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann. Neurol
69, 418–422. 10.1002/ana.22312</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.22312</ArticleId>
            <ArticleId IdType="pubmed">21387385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacob S, Viegas S, Leite MI, Webster R, Cossins J, Kennett R, Hilton-Jones D, Morgan BP, Vincent A, 2012. Presence and Pathogenic Relevance of Antibodies to Clustered Acetylcholine Receptor in Ocular and Generalized Myasthenia Gravis. Arch. Neurol
69. 10.1001/archneurol.2012.437</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2012.437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kao JC, Milone M, Selcen D, Shen X-M, Engel AG, Liewluck T, 2018. Congenital myasthenic syndromes in adult neurology clinic: A long road to diagnosis and therapy. Neurology
91, e1770–e1777. 10.1212/WNL.0000000000006478</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000006478</ArticleId>
            <ArticleId IdType="pmc">PMC6251603</ArticleId>
            <ArticleId IdType="pubmed">30291185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A, 2008. IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis†. Brain
131, 1940–1952. 10.1093/brain/awn092</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awn092</ArticleId>
            <ArticleId IdType="pmc">PMC2442426</ArticleId>
            <ArticleId IdType="pubmed">18515870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirian A, Nicolle MW, Edmond P, Budhram A, 2022. Comparison of fixed cell-based assay to radioimmunoprecipitation assay for acetylcholine receptor antibody detection in myasthenia gravis. J. Neurol. Sci
432, 120084. 10.1016/j.jns.2021.120084</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2021.120084</ArticleId>
            <ArticleId IdType="pubmed">34906880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park KH, Waters P, Woodhall M, Lang B, Smith T, Sung J-J, Kim K-K, Lim Y-M, Kim J-E, Kim B-J, Park J-S, Lim J-G, Kim D-S, Kwon O, Sohn EH, Bae JS, Yoon B-N, Kim N-H, Ahn S-W, Oh J, Park HJ, Shin KJ, Hong Y-H, 2018. Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: Autoantibody profiles and clinical features. PloS One
13, e0193723. 10.1371/joumal.pone.0193723</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/joumal.pone.0193723</ArticleId>
            <ArticleId IdType="pmc">PMC5843234</ArticleId>
            <ArticleId IdType="pubmed">29518096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prain K, Woodhall M, Vincent A, Ramanathan S, Barnett MH, Bundell CS, Parratt JDE, Silvestrini RA, Bukhari W, The Australian and New Zealand NMO Collaboration, Brilot F, Waters P, Broadley SA, 2019. AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD. Front. Neurol
10, 1028. 10.3389/fheur.2019.01028</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fheur.2019.01028</ArticleId>
            <ArticleId IdType="pmc">PMC6787171</ArticleId>
            <ArticleId IdType="pubmed">31636597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stathopoulos P, Chastre A, Waters P, Irani S, Fichtner ML, Benotti ES, Guthridge JM, Seifert J, Nowak RJ, Buckner JH, Holers VM, James JA, Hafler DA, O’Connor KC, 2019. Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity. J. Immunol. 202, 2210–2219. 10.4049/jimmunol.1801295</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1801295</ArticleId>
            <ArticleId IdType="pmc">PMC6452031</ArticleId>
            <ArticleId IdType="pubmed">30824481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe A, Su K-Y, Kuraoka M, Yang G, Reynolds AE, Schmidt AG, Harrison SC, Haynes BF, St. Clair EW, Kelsoe G, 2019. Self-tolerance curtails the B cell repertoire to microbial epitopes. JCI Insight
4, e122551. 10.1172/jci.insight.122551</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.122551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winklmeier S, Schlüter M, Spadaro M, Thaler FS, Vural A, Gerhards R, Macrini C, Mader S, Kurne A, Inan B, Karabudak R, Özbay FG, Esendagli G, Hohlfeld R, Kümpfel T, Meinl E, 2019. Identification of circulating MOG-specific B cells in patients with MOG antibodies. Neurol. - Neuroimmunol. Neuroinflammation
6, 625. 10.1212/NXI.0000000000000625</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000625</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
